An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery.
Phase of Trial: Phase I/II
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; VXM-01 (Primary) ; Ascorbic acid; Lactose; Sodium bicarbonate
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors VAXIMM
- 04 Jun 2019 Study design was presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 14 Oct 2018 Status changed from planning to recruiting.
- 17 May 2017 New trial record